RxDoctor Payments Data

Ajit Sawhney, MD

Nephrology · Fountain Valley, CANPI 1114014438

Payments from drug & device makers

$384,798in general payments, 2019–2025

Across 320 payments — averaging $1202.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$208K
  • Akebia Therapeutics Inc$68K
  • Eli Lilly$59K
  • Vifor Pharma, Inc.$37K
  • OPKO Pharmaceuticals, LLC$9K
  • Bayer$1K
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$9571%
  • Speaking & faculty fees$63,74572%
  • Travel & lodging$18,88221%
  • Food & beverage$5,3536%
  • Education$1070%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$384,798 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$55,700
Medicare patients
126
Services billed
494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol55$48,764
VeltassaPatiromer Calcium Sorbitex18$42,621
JardianceEmpagliflozin23$37,890
TradjentaLinagliptin43$31,915
RayaldeeCalcifediol13$9,280
AuryxiaFerric Citrate13$9,195
Cinacalcet Hcl17$8,225
Sevelamer Carbonate26$6,893
DapagliflozinDapagliflozin Propanediol13$5,417
Clonidine14$3,044
Losartan Potassium177$1,954
Comfort Ez Pen NeedlePen Needle, Diabetic18$1,547
Metoprolol Succinate57$1,351
Valsartan15$848
Hydralazine Hcl69$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$157$48,76455 claims
OPKO Pharmaceuticals, LLCRayaldee$9,186$9,28013 claims
Akebia Therapeutics IncAuryxia$68,089$9,19513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →